Reaffirmed: AstraZeneca PLC (LON:AZN) “Buy” Rating Reiterated by research analysts Deutsche Bank; GBX 5700.00 Target in Place

Share

AstraZeneca PLC (LON:AZN) Rating Reaffirmed

London: In analysts note distributed on 17 December, Deutsche Bank reiterated their “Buy” rating on AstraZeneca PLC (LON:AZN) shares. They now have a GBX 5700.00 target PPS on the company. Deutsche Bank’s target may imply a potential upside of 28.56% from the company’s last stock price.

From a total of 28 analysts covering AstraZeneca PLC (LON:AZN) stock, 18 rate it a ”Buy”, 6 a “Sell”, and 10 a ”Hold”. This means that 53% of the ratings are positive. The highest target price is GBX 95.38 while the lowest target price is GBX 36. The mean of all analyst targets is GBX 71.05 with a 8.81% above today’s (GBX 4433.63) stock price. AstraZeneca PLC was the topic of 122 analyst reports since July 23, 2015 according to the firm StockzIntelligence Inc. Bernstein maintained shares on December 10 with “Market Perform” rating. UBS maintained shares with “Buy” rating and GBX 5000 target share price in a report from a November 25. Jefferies maintained AZN stock in a recent report from December 7 with “Buy” rating. Credit Suisse maintained the rating on November 24. Credit Suisse has a “Underperform” rating and a GBX 4000 price target on shares. Finally, Morgan Stanley upgraded the stock to “Overweight” rating in a report issued on a December 1.

The stock increased 0.97% or GBX 42.63 on December 16, striking GBX 4433.63. Approximately 2.01M shares of stock traded hands. AstraZeneca plc (LON:AZN) has risen 0.53% since May 20, 2015 and is uptrending. It has outperformed by 3.16% the S&P500.

Reaffirmed: AstraZeneca PLC (LON:AZN)

AstraZeneca PLC is a global biopharmaceutical company. The company has a market cap of 55.61 billion GBP. The Firm discovers, develops and commercializes prescription medicines for Cardiovascular and Metabolic diseases; Oncology; Respiratory, Inflammation and Autoimmunity, Infection, Neuroscience and Gastrointestinal. It has 50.09 P/E ratio. The Company’s medicines include Crestor for managing cholesterol levels; Seloken/Toprol-XL for hypertension, heart failure and angina; Onglyza for Type 2; Iressa for lung cancer; Faslodex for breast cancer; Zoladex for prostate and breast cancer; Pulmicort for asthma; Symbicort for asthma and COPD (chronic obstructive pulmonary); Nexium for acid-related diseases; Seroquel XR for schizophrenia, bipolar disorder and depressive disorder, and Synagis for RSV (respiratory syncytial virus), a respiratory infection in infants.

According to Zacks Investment Research, “AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development, manufacture and marketing of ethical (prescription) pharmaceuticals and agricultural products, and the supply of healthcare services.”

COMMENTS: